- Home
- ALLO vs DCGO Comparison
ALLO vs DCGO Comparison
Compare ALLO & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- DCGO
- Stock Information
- Founded
- ALLO 2017
- DCGO 2015
- Country
- ALLO United States
- DCGO United States
- Employees
- ALLO N/A
- DCGO N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- DCGO Managed Health Care
- Sector
- ALLO Health Care
- DCGO Health Care
- Exchange
- ALLO Nasdaq
- DCGO Nasdaq
- Market Cap
- ALLO 427.7M
- DCGO 503.6M
- IPO Year
- ALLO 2018
- DCGO N/A
- Fundamental
- Price
- ALLO $2.17
- DCGO $4.79
- Analyst Decision
- ALLO Strong Buy
- DCGO Strong Buy
- Analyst Count
- ALLO 10
- DCGO 5
- Target Price
- ALLO $10.06
- DCGO $6.10
- AVG Volume (30 Days)
- ALLO 9.8M
- DCGO 702.8K
- Earning Date
- ALLO 03-13-2025
- DCGO 02-27-2025
- Dividend Yield
- ALLO N/A
- DCGO N/A
- EPS Growth
- ALLO N/A
- DCGO 300.38
- EPS
- ALLO N/A
- DCGO 0.29
- Revenue
- ALLO $43,000.00
- DCGO $694,968,328.00
- Revenue This Year
- ALLO N/A
- DCGO $2.14
- Revenue Next Year
- ALLO N/A
- DCGO N/A
- P/E Ratio
- ALLO N/A
- DCGO $16.79
- Revenue Growth
- ALLO 26.47
- DCGO 30.19
- 52 Week Low
- ALLO $1.32
- DCGO $2.75
- 52 Week High
- ALLO $5.78
- DCGO $5.68
- Technical
- Relative Strength Index (RSI)
- ALLO 55.14
- DCGO 45.48
- Support Level
- ALLO $1.32
- DCGO $5.25
- Resistance Level
- ALLO $3.78
- DCGO $5.68
- Average True Range (ATR)
- ALLO 0.36
- DCGO 0.24
- MACD
- ALLO 0.10
- DCGO -0.04
- Stochastic Oscillator
- ALLO 34.55
- DCGO 9.23
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.